Related Experiment Video
Updated: Nov 15, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Myeloid somatic mutation panel testing in myeloproliferative neoplasms.
David M Ross1, Candice Thomson2, Nada Hamad3
1Myeloproliferative Neoplasms Working Party, Australasian Leukaemia and Lymphoma Group, Melbourne, Vic, Australia; Department of Haematology and Bone Marrow Transplantation, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, SA, Australia.
Somatic mutation testing using next-generation sequencing (NGS) panels aids in diagnosing and predicting outcomes for myeloproliferative neoplasms. This approach enhances pathological assessment and guides targeted therapy selection.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myeloproliferative neoplasms (MPNs) involve mutations affecting cell growth, epigenetics, RNA splicing, or DNA repair.
- Understanding the mutational profile is crucial for MPN diagnosis, classification, prognosis, and targeted therapy.
- Next-generation sequencing (NGS) panels offer a practical method for analyzing numerous genetic variants.
Purpose of the Study:
- To review the diagnostic and prognostic significance of somatic mutation testing in Philadelphia-negative MPNs.
- To highlight the role of NGS panels in assessing various MPN subtypes.
Main Methods:
- Review of current literature on somatic mutation testing in MPNs.
- Focus on the application of NGS panels for genetic variant analysis.
Main Results:
- Somatic mutation profiling aids in the diagnosis and classification of MPNs.
- Mutational status provides prognostic information and can guide targeted treatment strategies.
- NGS panel testing is becoming standard practice for improved diagnostic accuracy and prognostic assessment.
Conclusions:
- Somatic mutation testing, particularly via NGS panels, is essential for managing Philadelphia-negative MPNs.
- This approach improves diagnostic precision and prognostic evaluation.
- NGS panel testing is poised to enhance the efficiency and accuracy of MPN pathology.
